aluates Reports

$ 0.0

Automative

Global Long-acting GLP-1 Therapy Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-12O20151

BUY CHAPTERS

Global Long-acting GLP-1 Therapy Market Research Report 2025

Code: QYRE-Auto-12O20151

Report

November 2025

Pages:67

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

AstraZeneca (legacy)

Long-acting GLP-1 Therapy Market Size

The global market for Long-acting GLP-1 Therapy was valued at US$ 23115 million in the year 2024 and is projected to reach a revised size of US$ 71426 million by 2031, growing at a CAGR of 19.0% during the forecast period.

Long-acting GLP-1 Therapy Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Long-acting GLP-1 Therapy competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Long-acting GLP-1 therapy means GLP-1–receptor–based medicines engineered to last a week (or longer) so they’re dosed once weekly rather than daily/twice-daily. They give steadier receptor activation for type 2 diabetes control and chronic weight management by boosting glucose-dependent insulin, slowing gastric emptying, and suppressing appetite. In 2024, global Long-acting GLP-1 Therapy production reached approximately 45234 K Unit, with an average global market price of around US$ 511 per unit.

Market outlook: GLP-1 therapies are set for sustained hypergrowth over the next 5–10 years as obesity care globalizes beyond type 2 diabetes, supported by compelling outcomes data, expanding payor coverage, and strong consumer pull for chronic weight management.

Industry chain (upstream→midstream): Upstream consists of peptide APIs (solid-phase synthesis, high-capacity preparative chromatography, PEGylation/lipidation linkers), device components (autoinjectors, pens, safety needles), and excipients, while midstream innovators integrate long-acting analog design, fill-finish, device pairing, and global regulatory/CMC to deliver branded combination drug–device products.

Downstream & ecosystem: Downstream demand flows through endocrinology and primary-care channels, obesity clinics, digital telehealth platforms, and employer/payer programs, with adherence, supply continuity, and step-therapy rules shaping real-world volumes and with compounding and biosimilar entry emerging as price/modality pressure over time.

Growth drivers & constraints: Growth is propelled by superior cardiometabolic outcomes (A1c, weight loss, CV risk signals), label and geography expansion, and pipeline next-gen incretin combos (GLP-1/GIP/GCGR), while constraints include manufacturing scale for complex peptides, device capacity, reimbursement variability, GI tolerability/attrition, and eventual price erosion from competition and biosimilars.

Economics (gross margins): At scale, branded GLP-1 drug–device products typically achieve ~75–90% gross margins for originators (high list prices, efficient peptide and device supply), ~20–35% for contract manufacturers/device suppliers, and ~10–20% for distribution/dispensing, with blended margins compressing over time as pricing pressure, rebates, and competitive entrants increase.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long-acting GLP-1 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting GLP-1 Therapy.

The Long-acting GLP-1 Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-acting GLP-1 Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, by Feature and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Long-acting GLP-1 Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Feature and by regions.

Scope of Long-acting GLP-1 Therapy Market Report

Report Metric	Details
Report Name	Long-acting GLP-1 Therapy Market
Accounted market size in year	US$ 23115 million
Forecasted market size in 2031	US$ 71426 million
CAGR	19.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Injection Oral
Segment by Feature	GLP-1 Receptor Agonists Co-agonists
Segment by Channel	Online Sales Offline Sales
Segment by Application	Type 2 Diabetes Obesity/Weight Management Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Eli Lilly, AstraZeneca (legacy)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Long-acting GLP-1 Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Long-acting GLP-1 Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Long-acting GLP-1 Therapy Market growing?

Ans: The Long-acting GLP-1 Therapy Market witnessing a CAGR of 19.0% during the forecast period 2025-2031.

What is the Long-acting GLP-1 Therapy Market size in 2031?

Ans: The Long-acting GLP-1 Therapy Market size in 2031 will be US$ 71426 million.

Who are the main players in the Long-acting GLP-1 Therapy Market report?

Ans: The main players in the Long-acting GLP-1 Therapy Market are Novo Nordisk, Eli Lilly, AstraZeneca (legacy)

What are the Application segmentation covered in the Long-acting GLP-1 Therapy Market report?

Ans: The Applications covered in the Long-acting GLP-1 Therapy Market report are Type 2 Diabetes, Obesity/Weight Management, Other

What are the Type segmentation covered in the Long-acting GLP-1 Therapy Market report?

Ans: The Types covered in the Long-acting GLP-1 Therapy Market report are Injection, Oral

1 Long-acting GLP-1 Therapy Market Overview

1.1 Product Definition

1.2 Long-acting GLP-1 Therapy by Type

1.2.1 Global Long-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031)

1.2.2 Injection

1.2.3 Oral

1.3 Long-acting GLP-1 Therapy by Feature

1.3.1 Global Long-acting GLP-1 Therapy Market Value Comparison by Feature: 2024 VS 2031

1.3.2 GLP-1 Receptor Agonists

1.3.3 Co-agonists

1.4 Long-acting GLP-1 Therapy by Channel

1.4.1 Global Long-acting GLP-1 Therapy Market Value Comparison by Channel: 2024 VS 2031

1.4.2 Online Sales

1.4.3 Offline Sales

1.5 Long-acting GLP-1 Therapy by Application

1.5.1 Global Long-acting GLP-1 Therapy Market Value by Application (2024 VS 2031)

1.5.2 Type 2 Diabetes

1.5.3 Obesity/Weight Management

1.5.4 Other

1.6 Global Long-acting GLP-1 Therapy Market Size Estimates and Forecasts

1.6.1 Global Long-acting GLP-1 Therapy Revenue 2020-2031

1.6.2 Global Long-acting GLP-1 Therapy Sales 2020-2031

1.6.3 Global Long-acting GLP-1 Therapy Market Average Price (2020-2031)

1.7 Assumptions and Limitations

2 Long-acting GLP-1 Therapy Market Competition by Manufacturers

2.1 Global Long-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)

2.2 Global Long-acting GLP-1 Therapy Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Long-acting GLP-1 Therapy Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Long-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Long-acting GLP-1 Therapy, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Long-acting GLP-1 Therapy, Product Type & Application

2.7 Global Key Manufacturers of Long-acting GLP-1 Therapy, Date of Enter into This Industry

2.8 Global Long-acting GLP-1 Therapy Market Competitive Situation and Trends

2.8.1 Global Long-acting GLP-1 Therapy Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Long-acting GLP-1 Therapy Players Market Share by Revenue

2.8.3 Global Long-acting GLP-1 Therapy Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Long-acting GLP-1 Therapy Market Scenario by Region

3.1 Global Long-acting GLP-1 Therapy Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Long-acting GLP-1 Therapy Sales by Region: 2020-2031

3.2.1 Global Long-acting GLP-1 Therapy Sales by Region: 2020-2025

3.2.2 Global Long-acting GLP-1 Therapy Sales by Region: 2026-2031

3.3 Global Long-acting GLP-1 Therapy Revenue by Region: 2020-2031

3.3.1 Global Long-acting GLP-1 Therapy Revenue by Region: 2020-2025

3.3.2 Global Long-acting GLP-1 Therapy Revenue by Region: 2026-2031

3.4 North America Long-acting GLP-1 Therapy Market Facts & Figures by Country

3.4.1 North America Long-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Long-acting GLP-1 Therapy Sales by Country (2020-2031)

3.4.3 North America Long-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Long-acting GLP-1 Therapy Market Facts & Figures by Country

3.5.1 Europe Long-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Long-acting GLP-1 Therapy Sales by Country (2020-2031)

3.5.3 Europe Long-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Long-acting GLP-1 Therapy Market Facts & Figures by Region

3.6.1 Asia Pacific Long-acting GLP-1 Therapy Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Long-acting GLP-1 Therapy Sales by Region (2020-2031)

3.6.3 Asia Pacific Long-acting GLP-1 Therapy Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Long-acting GLP-1 Therapy Market Facts & Figures by Country

3.7.1 Latin America Long-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Long-acting GLP-1 Therapy Sales by Country (2020-2031)

3.7.3 Latin America Long-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Long-acting GLP-1 Therapy Market Facts & Figures by Country

3.8.1 Middle East and Africa Long-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Long-acting GLP-1 Therapy Sales by Country (2020-2031)

3.8.3 Middle East and Africa Long-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Long-acting GLP-1 Therapy Sales by Type (2020-2031)

4.1.1 Global Long-acting GLP-1 Therapy Sales by Type (2020-2025)

4.1.2 Global Long-acting GLP-1 Therapy Sales by Type (2026-2031)

4.1.3 Global Long-acting GLP-1 Therapy Sales Market Share by Type (2020-2031)

4.2 Global Long-acting GLP-1 Therapy Revenue by Type (2020-2031)

4.2.1 Global Long-acting GLP-1 Therapy Revenue by Type (2020-2025)

4.2.2 Global Long-acting GLP-1 Therapy Revenue by Type (2026-2031)

4.2.3 Global Long-acting GLP-1 Therapy Revenue Market Share by Type (2020-2031)

4.3 Global Long-acting GLP-1 Therapy Price by Type (2020-2031)

5 Segment by Application

5.1 Global Long-acting GLP-1 Therapy Sales by Application (2020-2031)

5.1.1 Global Long-acting GLP-1 Therapy Sales by Application (2020-2025)

5.1.2 Global Long-acting GLP-1 Therapy Sales by Application (2026-2031)

5.1.3 Global Long-acting GLP-1 Therapy Sales Market Share by Application (2020-2031)

5.2 Global Long-acting GLP-1 Therapy Revenue by Application (2020-2031)

5.2.1 Global Long-acting GLP-1 Therapy Revenue by Application (2020-2025)

5.2.2 Global Long-acting GLP-1 Therapy Revenue by Application (2026-2031)

5.2.3 Global Long-acting GLP-1 Therapy Revenue Market Share by Application (2020-2031)

5.3 Global Long-acting GLP-1 Therapy Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Long-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novo Nordisk Long-acting GLP-1 Therapy Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly Long-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Eli Lilly Long-acting GLP-1 Therapy Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 AstraZeneca (legacy)

6.3.1 AstraZeneca (legacy) Company Information

6.3.2 AstraZeneca (legacy) Description and Business Overview

6.3.3 AstraZeneca (legacy) Long-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.3.4 AstraZeneca (legacy) Long-acting GLP-1 Therapy Product Portfolio

6.3.5 AstraZeneca (legacy) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Long-acting GLP-1 Therapy Industry Chain Analysis

7.2 Long-acting GLP-1 Therapy Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Long-acting GLP-1 Therapy Production Mode & Process Analysis

7.4 Long-acting GLP-1 Therapy Sales and Marketing

7.4.1 Long-acting GLP-1 Therapy Sales Channels

7.4.2 Long-acting GLP-1 Therapy Distributors

7.5 Long-acting GLP-1 Therapy Customer Analysis

8 Long-acting GLP-1 Therapy Market Dynamics

8.1 Long-acting GLP-1 Therapy Industry Trends

8.2 Long-acting GLP-1 Therapy Market Drivers

8.3 Long-acting GLP-1 Therapy Market Challenges

8.4 Long-acting GLP-1 Therapy Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

AstraZeneca (legacy)

List of Tables

Table 1. Global Long-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Long-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2024 VS 2031)

Table 3. Global Long-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2024 VS 2031)

Table 4. Global Long-acting GLP-1 Therapy Market Value by Application (2024 VS 2031) & (US$ Million)

Table 5. Global Long-acting GLP-1 Therapy Market Competitive Situation by Manufacturers in 2024

Table 6. Global Long-acting GLP-1 Therapy Sales (K Units) of Key Manufacturers (2020-2025)

Table 7. Global Long-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)

Table 8. Global Long-acting GLP-1 Therapy Revenue (US$ Million) by Manufacturers (2020-2025)

Table 9. Global Long-acting GLP-1 Therapy Revenue Share by Manufacturers (2020-2025)

Table 10. Global Market Long-acting GLP-1 Therapy Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 11. Global Key Players of Long-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024

Table 12. Global Key Manufacturers of Long-acting GLP-1 Therapy, Manufacturing Sites & Headquarters

Table 13. Global Key Manufacturers of Long-acting GLP-1 Therapy, Product Type & Application

Table 14. Global Key Manufacturers of Long-acting GLP-1 Therapy, Date of Enter into This Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Long-acting GLP-1 Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting GLP-1 Therapy as of 2024)

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Long-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global Long-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)

Table 20. Global Long-acting GLP-1 Therapy Sales Market Share by Region (2020-2025)

Table 21. Global Long-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)

Table 22. Global Long-acting GLP-1 Therapy Sales Market Share by Region (2026-2031)

Table 23. Global Long-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 24. Global Long-acting GLP-1 Therapy Revenue Market Share by Region (2020-2025)

Table 25. Global Long-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)

Table 26. Global Long-acting GLP-1 Therapy Revenue Market Share by Region (2026-2031)

Table 27. North America Long-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. North America Long-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 29. North America Long-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 30. North America Long-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 31. North America Long-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 32. Europe Long-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 33. Europe Long-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 34. Europe Long-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 35. Europe Long-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 36. Europe Long-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 37. Asia Pacific Long-acting GLP-1 Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 38. Asia Pacific Long-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)

Table 39. Asia Pacific Long-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)

Table 40. Asia Pacific Long-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 41. Asia Pacific Long-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)

Table 42. Latin America Long-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Latin America Long-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 44. Latin America Long-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 45. Latin America Long-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 46. Latin America Long-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 47. Middle East and Africa Long-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 48. Middle East and Africa Long-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 49. Middle East and Africa Long-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 50. Middle East and Africa Long-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 51. Middle East and Africa Long-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 52. Global Long-acting GLP-1 Therapy Sales (K Units) by Type (2020-2025)

Table 53. Global Long-acting GLP-1 Therapy Sales (K Units) by Type (2026-2031)

Table 54. Global Long-acting GLP-1 Therapy Sales Market Share by Type (2020-2025)

Table 55. Global Long-acting GLP-1 Therapy Sales Market Share by Type (2026-2031)

Table 56. Global Long-acting GLP-1 Therapy Revenue (US$ Million) by Type (2020-2025)

Table 57. Global Long-acting GLP-1 Therapy Revenue (US$ Million) by Type (2026-2031)

Table 58. Global Long-acting GLP-1 Therapy Revenue Market Share by Type (2020-2025)

Table 59. Global Long-acting GLP-1 Therapy Revenue Market Share by Type (2026-2031)

Table 60. Global Long-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2025)

Table 61. Global Long-acting GLP-1 Therapy Price (US$/Unit) by Type (2026-2031)

Table 62. Global Long-acting GLP-1 Therapy Sales (K Units) by Application (2020-2025)

Table 63. Global Long-acting GLP-1 Therapy Sales (K Units) by Application (2026-2031)

Table 64. Global Long-acting GLP-1 Therapy Sales Market Share by Application (2020-2025)

Table 65. Global Long-acting GLP-1 Therapy Sales Market Share by Application (2026-2031)

Table 66. Global Long-acting GLP-1 Therapy Revenue (US$ Million) by Application (2020-2025)

Table 67. Global Long-acting GLP-1 Therapy Revenue (US$ Million) by Application (2026-2031)

Table 68. Global Long-acting GLP-1 Therapy Revenue Market Share by Application (2020-2025)

Table 69. Global Long-acting GLP-1 Therapy Revenue Market Share by Application (2026-2031)

Table 70. Global Long-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2025)

Table 71. Global Long-acting GLP-1 Therapy Price (US$/Unit) by Application (2026-2031)

Table 72. Novo Nordisk Company Information

Table 73. Novo Nordisk Description and Business Overview

Table 74. Novo Nordisk Long-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Novo Nordisk Long-acting GLP-1 Therapy Product

Table 76. Novo Nordisk Recent Developments/Updates

Table 77. Eli Lilly Company Information

Table 78. Eli Lilly Description and Business Overview

Table 79. Eli Lilly Long-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Eli Lilly Long-acting GLP-1 Therapy Product

Table 81. Eli Lilly Recent Developments/Updates

Table 82. AstraZeneca (legacy) Company Information

Table 83. AstraZeneca (legacy) Description and Business Overview

Table 84. AstraZeneca (legacy) Long-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. AstraZeneca (legacy) Long-acting GLP-1 Therapy Product

Table 86. AstraZeneca (legacy) Recent Developments/Updates

Table 87. Key Raw Materials Lists

Table 88. Raw Materials Key Suppliers Lists

Table 89. Long-acting GLP-1 Therapy Distributors List

Table 90. Long-acting GLP-1 Therapy Customers List

Table 91. Long-acting GLP-1 Therapy Market Trends

Table 92. Long-acting GLP-1 Therapy Market Drivers

Table 93. Long-acting GLP-1 Therapy Market Challenges

Table 94. Long-acting GLP-1 Therapy Market Restraints

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Authors List of This Report

List of Figures

Figure 1. Product Picture of Long-acting GLP-1 Therapy

Figure 2. Global Long-acting GLP-1 Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Long-acting GLP-1 Therapy Market Share by Type: 2024 & 2031

Figure 4. Injection Product Picture

Figure 5. Oral Product Picture

Figure 6. Global Long-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2020-2031)

Figure 7. Global Long-acting GLP-1 Therapy Market Share by Feature: 2024 VS 2031

Figure 8. GLP-1 Receptor Agonists Product Picture

Figure 9. Co-agonists Product Picture

Figure 10. Global Long-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2020-2031)

Figure 11. Global Long-acting GLP-1 Therapy Market Share by Channel: 2024 VS 2031

Figure 12. Online Sales Product Picture

Figure 13. Offline Sales Product Picture

Figure 14. Global Long-acting GLP-1 Therapy Market Value by Application (2020-2031) & (US$ Million)

Figure 15. Global Long-acting GLP-1 Therapy Market Share by Application: 2024 & 2031

Figure 16. Type 2 Diabetes

Figure 17. Obesity/Weight Management

Figure 18. Other

Figure 19. Global Long-acting GLP-1 Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 20. Global Long-acting GLP-1 Therapy Market Size (2020-2031) & (US$ Million)

Figure 21. Global Long-acting GLP-1 Therapy Sales (2020-2031) & (K Units)

Figure 22. Global Long-acting GLP-1 Therapy Average Price (US$/Unit) & (2020-2031)

Figure 23. Long-acting GLP-1 Therapy Report Years Considered

Figure 24. Long-acting GLP-1 Therapy Sales Share by Manufacturers in 2024

Figure 25. Global Long-acting GLP-1 Therapy Revenue Share by Manufacturers in 2024

Figure 26. Global 5 and 10 Largest Long-acting GLP-1 Therapy Players: Market Share by Revenue in Long-acting GLP-1 Therapy in 2024

Figure 27. Long-acting GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 28. Global Long-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 29. North America Long-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 30. North America Long-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 31. United States Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Canada Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Europe Long-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 34. Europe Long-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 35. Germany Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. France Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. U.K. Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Italy Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Russia Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Asia Pacific Long-acting GLP-1 Therapy Sales Market Share by Region (2020-2031)

Figure 41. Asia Pacific Long-acting GLP-1 Therapy Revenue Market Share by Region (2020-2031)

Figure 42. China Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Japan Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. South Korea Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. India Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Australia Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. China Taiwan Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Southeast Asia Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America Long-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 50. Latin America Long-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 51. Mexico Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Colombia Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Middle East and Africa Long-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 56. Middle East and Africa Long-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 57. Turkey Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Saudi Arabia Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. UAE Long-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 60. Global Sales Market Share of Long-acting GLP-1 Therapy by Type (2020-2031)

Figure 61. Global Revenue Market Share of Long-acting GLP-1 Therapy by Type (2020-2031)

Figure 62. Global Long-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2031)

Figure 63. Global Sales Market Share of Long-acting GLP-1 Therapy by Application (2020-2031)

Figure 64. Global Revenue Market Share of Long-acting GLP-1 Therapy by Application (2020-2031)

Figure 65. Global Long-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2031)

Figure 66. Long-acting GLP-1 Therapy Value Chain

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions